Investors

All our Financial Information

Investors

All our Financial Information

The SpineJack® is becoming a standard for the treatment of vertebral fractures and VEXIM’s technology has been embraced by several key opinion leaders. We can already confirm we have reached the milestone of 40,000 implants sold – which represents approximatively more than 20,000 patients.
We will build on this success and on our leading technology platform to extend our product offering and target new pathologies in spine trauma by 2018.

LIVE STOCK QUOTE

EPA:

05 Dec - 15:24 UTC+00:00

Eur (0%)

Investor Guide

VEXIM shows great opportunities

and now heads towards autonomy

and financial independence.

FINANCIAL KEY FIGURES

CUMULATED SALES

as of December 31st, 2016

€18.5 M

+33%

GROSS MARGIN

as of December 31st, 2016

€13.4 M

+72.2% of sales

CASH POSITION

as of December 31st, 2016

€9.8 M

  

FINANCIAL KEY FIGURES

&nbsp

Find our lastest Press Releases and Newsletters

Find our lastest Press Releases and Newsletters

Discover our Solutions

Discover our Solutions

>>

Our History

Our History

Subscribe to Investor Communication

Subscribe to Investor Communication